Table 1.
Baseline characteristics in the training set and validation set
| Variable | Training set n=122 |
Validation set n=61 |
P-value difference between training and validation sets | ||||
|---|---|---|---|---|---|---|---|
| A-LMR ≥1 (n=73) |
A-LMR <1 (n=49) |
P-value | A-LMR ≥1 (n=36) |
A-LMR <1 (n=25) |
P-value | ||
| At diagnosis | |||||||
| Age, years, median (range) | 30 (19–69) | 32 (17–66) | 0.7 | 32 (19–60) | 34 (18–71) | 0.9 | 0.6 |
| Sex | 0.3 | 0.3 | 0.4 | ||||
| Male | 32 (44%) | 27 (55%) | 18 (50%) | 16 (64%) | |||
| Female | 41 (56%) | 22 (45%) | 18 (31%) | 9 (36%) | |||
| Albumin (g/dL), median (range) | 4.1 (1.0–4.7) | 4.1 (2.7–4.7) | 0.5 | 4.2 (2.6–4.9) | 4.2 (2.5–4.9) | 0.5 | 0.1 |
| ALC ×109/L, median (range) | 1.16 (0.3–3.4) | 1.02 (0.06–3.25) | 0.06 | 1.09 (0.19–2.74) | 0.87 (0.19–3.76) | 0.1 | 0.2 |
| Hemoglobin (g/dL), median (range) | 12.1 (7.3–16.0) | 12 (6.9–15.4) | 0.5 | 12.1 (8.1–17.2) | 11.9 (9.4–15.2) | 0.4 | 0.9 |
| Stage | 0.8 | 0.2 | 0.4 | ||||
| 1 | 0 (0%) | 0 (90%) | 1 (3%) | 0 (0%) | |||
| 2 | 33 (46%) | 21 (43%) | 13 (36%) | 11 (44%) | |||
| 3 | 20 (27%) | 12 (24%) | 15 (42%) | 5 (20%) | |||
| 4 | 20 (27%) | 16 (33%) | 7 (19%) | 9 (36%) | |||
| WBC ×109/L, median (range) | 8.4 (2.8–20.1) | 8.9 (1.1–22.8) | 0.2 | 7.4 (2.0–20.1) | 6.7 (1.1–20.7) | 0.8 | 0.1 |
| IPS risk factors | |||||||
| Age, years | 0.9 | 0.8 | 0.9 | ||||
| >45 | 17 (23%) | 12 (24%) | 8 (22%) | 6 (24%) | |||
| ≤45 | 56 (77%) | 37 (76%) | 28 (78%) | 19 (76%) | |||
| Albumin (g/dL) | 0.9 | 0.4 | 0.5 | ||||
| >1 | 41 (59%) | 27 (59%) | 24 (69%) | 14 (48%) | |||
| ≤1 | 29 (41%) | 19 (41%) | 11 (31%) | 10 (42%) | |||
| ALC-DX ×109/L | 0.3 | 0.7 | 0.1 | ||||
| ≥0.6 | 47 (64%) | 26 (53%) | 21 (58%) | 8 (32%) | |||
| <0.6 | 26 (36%) | 23 (47%) | 15 (42%) | 17 (68%) | |||
| Hemoglobin (g/dL) | <0.02 | 0.4 | 0.9 | ||||
| >10.5 | 62 (84%) | 31 (65%) | 26 (74%) | 22 (85%) | |||
| ≤10.5 | 12 (16%) | 17 (35%) | 9 (26%) | 4 (15%) | |||
| Stage 4 | 0.5 | 0.2 | 0.7 | ||||
| Yes | 20 (27%) | 16 (33%) | 7 (81%) | 9 (36%) | |||
| No | 53 (73%) | 33 (67%) | 29 (19%) | 16 (64%) | |||
| WBC ×109/L | 0.4 | 0.7 | 0.9 | ||||
| <15 | 10 (8%) | 5 (10%) | 5 (14%) | 2 (8%) | |||
| ≤15 | 63 (92%) | 44 (90%) | 30 (86%) | 23 (92%) | |||
| Number of IPS factors | 0.3 | 0.09 | 0.4 | ||||
| 0 | 11 (15%) | 3 (6%) | 5 (14%) | 3 (125) | |||
| 1 | 29 (40%) | 15 (31%) | 15 (42%) | 4 (16%) | |||
| 2 | 14 (19%) | 13 (26%) | 8 (22%) | 9 (36%) | |||
| 3 | 14 (19%) | 14 (29%) | 6 (16%) | 3 (12%) | |||
| 4 | 4 (6%) | 2 (4%) | 1 (3%) | 4 (16%) | |||
| 5 | 1 (1%) | 2 (4%) | 0 (0%) | 2 (8%) | |||
| 6 | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | |||
| IPS index | 0.2 | 0.3 | 0.7 | ||||
| ≥3 | 19 (26%) | 18 (37%) | 8 (22%) | 9 (36%) | |||
| <3 | 54 (74%) | 31 (63%) | 28 (78%) | 16 (64%) | |||
| Initial chemotherapy | 0.5 | 0.5 | 0.6 | ||||
| ABVD | 71 (98%) | 49 (100%) | 36 (100%) | 24 (96%) | |||
| Stanford V | 1 (1%) | 0 (0%) | 0 (0%) | 1 (4%) | |||
| MOPP | 1 (1%) | 0 (%) | 0 (0%) | 0 (0%) | |||
| Salvage chemotherapy | 0.8 | 0.4 | 0.6 | ||||
| ICE | 50 (69%) | 32 (65%) | 26 (72%) | 17 (68%) | |||
| DHAP | 18 (25%) | 15 (31%) | 9 (25%) | 5 (20%) | |||
| MOPP | 1 (1%) | 1 (2%) | 1 (2%) | 2 (8%) | |||
| EPOCH | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
| ESHAP | 2 (3%) | 1 (2%) | 0 (0%) | 1 (4%) | |||
| GVD | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
| At transplant | |||||||
| Clinical status pre-transplant | 0.4 | 0.3 | 0.6 | ||||
| Complete response | 20 (27%) | 8 (16%) | 17 (47%) | 7 (28%) | |||
| Partial response | 39 (53%) | 30 (61%) | 12 (33%) | 13 (52%) | |||
| Refractory | 14 (20%) | 11 (23%) | 7 (20%) | 5 (20%) | |||
| Plerixafor | 0.2 | 0.7 | 0.4 | ||||
| Yes | 18 (25%) | 7 (14%) | 6 (17%) | 3 (12%) | |||
| No | 55 (75%) | 42 (86%) | 30 (83%) | 22 (88%) | |||
| Conditioning regimens | 0.1 | 0.1 | 0.9 | ||||
| CBV | 3 (4%) | 6 (12%) | 1 (3%) | 4 (16%) | |||
| BEAM | 70 (96%) | 43 (88%) | 35 (97%) | 21 (84%) | |||
| Infused CD34, median (range) | 5.3 (2.0–14.5) | 5.2 (2.0–16.1) | 0.5 | 5.5 (2.9–10.1) | 4.9 (2.0–11.3) | 0.1 | 0.7 |
| A-ALC, median (range) | 0.78 (0.21–2.18) | 0.39 (0.03–1.42) | <0.0001 | 0.80 (0.32–2.61) | 0.39 (0.04–2.01) | <0.0001 | 0.8 |
| A-AMC, median (range) | 0.47 (0.01–1.38) | 0.76 (0.14–1.97) | <0.0001 | 0.49 (0.11–1.90) | 0.75 (0.24–2.41) | <0.0001 | 0.1 |
| ALC-15, median (range) | 0.96 (0.16–3.19) | 0.48 (0.01–2.35) | <0.0001 | 0.95 (0.34–4.12) | 0.48 (0.29–1.83) | <0.0001 | 0.8 |
| AMC-15, median (range) | 0.34 (0.05–1.4) | 0.74 (0.04–7.47) | <0.0001 | 0.6 (0.02–1.77) | 0.8 (0.05–2.29) | <0.001 | 0.2 |
| LMR-15 | 1.7 (0.91–16) | 0.64 (0.79–4.16) | <0.0001 | 1.57 (0.82–3.7) | 0.77 (0.27–9) | <0.0001 | 0.8 |
Abbreviations: A-ALC, autograft absolute lymphocyte count; A-AMC, autograft absolute monocyte count; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; ALC, absolute lymphocyte count; ALC-15, absolute lymphocyte count at day 15 post-transplantation; ALC-DX, absolute lymphocyte count at diagnosis; A-LMR, autograft lymphocyte/monocyte ratio; AMC-15, absolute monocyte count at day 15 post-transplantation; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; DHAP, dexamethasone, cytarabine, and cisplatin; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, and adriamycin; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; GVD, Gemzar®, vinorelbine, and liposomal doxorubicin; ICE, ifosfamide, carboplatin, and etoposide; IPS, International Prognostic Score; LMR-15, lymphocyte to monocyte ratio at day 15 post-transplantation; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; WBC, white blood cell count.